Antipsychotic Drugs Market Forecasts 2023-2028 - Market Set for Growth, Forecasted at CAGR of 5.94% from 2023 to 2028

DUBLIN, Dec. 15, 2023 /PRNewswire/ -- The "Antipsychotic Drugs Market Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering.

With mental health issues on the rise globally, the demand for effective treatment options has become a public health priority. A new research publication highlighting the expanding trajectory of the antipsychotic drugs market is now available, underscoring significant market growth and the introduction of innovative treatment solutions.

The global antipsychotic drugs market, which was valued at US$15.214 billion in 2021, is projected to experience robust growth in the coming years, with expectations to reach US$22.783 billion by 2028. This represents a healthy compound annual growth rate (CAGR) of 5.94%, indicating a market that responds dynamically to the increasing prevalence of mental health disorders such as schizophrenia and bipolar disorder, among others.

Market Dynamics and Opportunities

The new report analyses several market drivers propelling the antipsychotic drugs industry forward. The rise in mental health issues, alongside increasing clinical trials and innovations in antipsychotic medications, lay the foundation for significant market growth. Retail pharmacies enhance access and distribution, playing a vital role in the market's expansion.

Moreover, the accelerated prevalence of mental health disorders underpins the expanding need for effective treatments. Depression in the younger generation is a particular concern, with worldwide data pointing to a dire need for accessible and reliable antipsychotic drug therapy options.

The commitment of government entities to improve mental health services and increase awareness is another pivotal factor stimulating market growth. Public health campaigns and improved funding for research into mental health conditions are vital components contributing to the development of this sector.

Geographic and Segment Insights

• North America's antipsychotic drugs market, spurred by a robust regulatory framework and heightened disease prevalence, is expected to witness considerable growth.
• The market is segmented by therapeutic class, application, distribution channel, and geographic region.
• The therapeutic class consists of first-generation and second-generation antipsychotic drugs, catering to various patient needs.
• Applications of these drugs are widespread, ranging from schizophrenia and dementia to bipolar disorder and depression.
• Distribution channels feature hospital pharmacies, retail pharmacies, and online pharmacies – each serving critical roles in medication accessibility.

Market Developments and Segment Expansion

Recent advancements in the antipsychotic drugs market include new indications for existing medications, encouraging phase trial results, and initiatives for better treatment delivery. These developments are indicative of the industry's commitment to innovation and improved patient outcomes.

With a spotlight on schizophrenia, the antipsychotic drugs market is making strides in addressing the needs of a demographic that showcases early onset of symptoms, demanding effective management and therapeutic interventions.

The comprehensive analysis provided in this new research reveals the intricate fabric of the antipsychotic drugs market, offering an in-depth understanding of current trends, market dynamics, and prospective developments. For stakeholders, healthcare providers, and patients, this report becomes a crucial tool in navigating the complexities of mental health treatment and pharmaceutical advancements.

This detailed examination of the antipsychotic drugs market contributes to a nuanced understanding of the industry's current state and its potential, heralding a period of sustained growth and development over the coming years.

Companies Profiled

• AstraZeneca
• Pfizer
• Alkermes
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Johnson and Johnson
• Teva Pharmaceutical Industries
• Otsuka Holdings
• AbbVie

Key Topics Covered:

1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
4.4. Industry Value Chain Analysis

5. ANTI-PSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS
5.1. Introduction
5.2. First-generation
5.3. Second-generation

6. ANTI-PSYCHOTIC DRUGS MARKET, BY APPLICATION
6.1. Introduction
6.2. Schizophrenia
6.3. Dementia
6.4. Bipolar Disorder
6.5. Depression
6.6. Others

7. ANTI-PSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Retail Pharmacies
7.4. Online Pharmacies

8. ANTI-PSYCHOTIC DRUGS MARKET, BY GEOGRAPHY

9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

For more information about this report visit https://www.researchandmarkets.com/r/hhcd0q

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED